Olfr681, encoded by the Or56a3b gene, is a member of the olfactory receptor family in Mus musculus, belonging to the G-protein-coupled receptor (GPCR) superfamily. These receptors are essential for olfaction, detecting odorant molecules in the nasal epithelium and initiating neuronal responses that lead to the perception of smells. The structure of olfactory receptors, including Olfr681, features a 7-transmembrane domain typical of many neurotransmitter and hormone receptors. They are responsible for recognizing odorants and initiating G protein-mediated signal transduction, a process involving activation of downstream signaling pathways, often mediated by changes in second messengers like cyclic AMP (cAMP). Inhibiting Olfr681 is challenging due to the intricate nature of GPCR signaling pathways and the lack of direct, specific inhibitors. Therefore, the focus shifts to potential indirect inhibitors that modulate related signaling pathways or cellular processes. Beta-adrenergic receptor antagonists, such as propranolol, atenolol, and metoprolol, reduce cellular cAMP levels, a crucial component in GPCR signaling. This reduction in cAMP could indirectly affect the signaling pathways of GPCRs, potentially influencing the function of olfactory receptors like Olfr681. Additionally, calcium channel blockers like nifedipine and verapamil alter intracellular calcium levels, another vital factor in GPCR signaling. Changes in calcium dynamics can indirectly influence the function of GPCRs, including olfactory receptors.
Targeting other GPCR pathways, such as those modulated by angiotensin II receptors, offers another indirect approach to modulate olfactory receptor function. Antagonists like losartan and candesartan might alter the GPCR signaling environment, potentially affecting receptors like Olfr681. Alpha-2 adrenergic receptor modulation by agents like yohimbine and clonidine could also indirectly impact GPCR signaling mechanisms, including those of olfactory receptors. In conclusion, the indirect inhibition of Olfr681 involves understanding GPCR biology and the interconnected nature of cellular signaling pathways. The chemicals listed offer insights into potential mechanisms for influencing the activity of olfactory receptors like Olfr681. While direct inhibition presents significant challenges, these indirect approaches provide potential strategies for modulating the receptor's function within the complex network of GPCR signaling.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol, a non-selective beta-adrenergic antagonist, lowers cAMP levels by inhibiting beta-adrenergic receptors, potentially affecting GPCR-mediated pathways relevant to Olfr681. | ||||||
(RS)-Atenolol | 29122-68-7 | sc-204895 sc-204895A | 1 g 10 g | $79.00 $416.00 | 1 | |
Atenolol, a β1-adrenergic receptor antagonist, decreases cAMP levels, potentially influencing GPCR signaling pathways and indirectly impacting Olfr681 function. | ||||||
Metoprolol Tartrate | 56392-17-7 | sc-205751 sc-205751A | 5 g 25 g | $107.00 $243.00 | 3 | |
Metoprolol, a β1-adrenergic receptor blocker, may indirectly affect GPCR signaling by altering β1 receptor activity, potentially impacting Olfr681. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine, a calcium channel blocker, modulates intracellular calcium levels, potentially impacting GPCR-mediated pathways and indirectly affecting Olfr681. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil, a calcium channel blocker, can indirectly influence GPCR signaling through altered calcium dynamics, potentially impacting Olfr681. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
Carvedilol, with beta-adrenergic antagonist and alpha-1 blocking activity, might modulate GPCR-mediated signaling, potentially influencing Olfr681. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Losartan, an angiotensin II receptor antagonist, affects GPCR signaling by inhibiting AT1 receptors, potentially indirectly impacting Olfr681. | ||||||
Candesartan | 139481-59-7 | sc-217825 sc-217825B sc-217825A | 10 mg 100 mg 1 g | $47.00 $94.00 $151.00 | 6 | |
Candesartan, an angiotensin II receptor blocker, could indirectly modulate GPCR signaling pathways, influencing Olfr681. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Yohimbine, an alpha-2 adrenergic receptor antagonist, can indirectly affect GPCR signaling, potentially influencing Olfr681. | ||||||
Nadolol | 42200-33-9 | sc-253175 | 1 g | $184.00 | ||
Nadolol, a non-selective beta-adrenergic receptor blocker, indirectly influences GPCR signaling, which could impact Olfr681. | ||||||